Metastatic HER2 Kansarka Naasaha ee Ku-Meel-Gaarka ah: Daaweynta iyo La-qabsiga

Waa Maxay Daaweynta Wanaagsan ee loogu talagalay Heerka 4 HER2-Kansarka Kansarka Naasaha?

Haddii lagugu ogaado kansarka naasaha 'HER2-positive', waxaa laga yaabaa in macluumaadka badankood ee aad ka hesho ay ka hadlaan kansarka hore ama marxalada 4 kaankarada naasaha guud ahaan. Maxaad u baahan tahay inaad ka ogaato daaweynta marxaladda 4 kaankarada naasaha oo ah HER2 sax?

Daaweynta HER2 Kansarka Naasaha ee Waxtarka leh

Waxaa laga yaabaa inaad baratay in aad leedahay heer kiniin ah 4 (metastatic) kansarka naasaha marka ugu horreysa ee lagugu ogaado cudurka, laakiin inta badan, metastasada fog waxay u dhacdaa dib u soo noqoshada buro oo markii hore horey u jirtey buro hore.

Sidan oo kale, cudurka dabiiciga ah wuxuu inta badan yimaadaa naxdin wuxuuna dareemayaa inuu dareemo culus.

Ma aha oo keliya in natiijadu tahay mid aan fiicneyn marka kansarka naasuhu ku faafo, laakiin fikirka ah in daaweynta mar labaad la sii wadi karo ayaa ka tagi karta inaad dareentid niyad jab. Inkastoo marxaladda 4 HER2 kansarka naasaha naasaha aan la daaweyn karin, waa daweyn, iyo daweyno loogu talagalay in lagu beegsado HER2 waxay sii wadi doontaa fidinta iyo horumarinta. Daawooyinkaas badanaaba waxay leeyihiin waxyeelo ka yar daawooyinka kemotherabi.

Qiyaastii mid ka mid ah shan ka mid ah kansarrada naasaha waa kansarka naasaha ee HER2-positive . Tani waxay ka dhigan tahay in kansarka naasaha qaarkood ay leeyihiin HER2 gen oo kor u qaadaya borotiinka HER2. Barootigaani waxay ku xidhan yihiin unugyada kansarka naasaha, taasoo keenaysa sifooyinka koritaanka burooyinkaas. Guud ahaan, HER2 burooyinka naasaha ayaa ah kuwa gardarada ah oo si degdeg ah u koraya.

Ilaa iyo intii 1998, markii Herceptin la oggolaaday, HER2 burooyin haleelay waxay leeyihiin qanjirro sabool ah, gaar ahaan kuwa iyagu sidoo kale ku jiray buro cajiin ah oo hormoon ah oo hormoon ah iyo progesterone.

Laga soo bilaabo waqtigaa kale oo la bartilmaameedsanayo daroogooyinka ayaa sidoo kale la sameeyey kaas oo sidoo kale bartilmaameedsanaya HER2, isaga oo ka tagaya fursadaha xitaa marka hal daroogo, ama xataa laba, ay ku fashilmaan

Isbedelada Xaaladda Degdega ah

Dad badan ayaa la yaabay inay bartaan in xaalad xasaasiyadeed ee kansarkooda la beddelo ka dib markii la soo celiyo. Haddii aad qabtid hindhicir xasaasiyadeed oo loo yaqaan 'estrogen positive ' markii lagaa helay kansarka naasaha hore, dib-u-soo-celintu waxay noqon kartaa mid aan caadi aheyn (ama ka duwan).

Sidoo kale, haddii aad hore u yeelatay buro HER2 / neu ah, waxaa laga yaabaa inay hadda tahay wax xun ama hadda ah.

Tani waa sababta keentay cad ka-qaadista iyo dib-u-eegista xaalad-qaadaha ee dib-u-baadhista waa mid aad muhiim u ah haddii aad qabtid dib-u-dhac fara badan oo cudurkaaga ah.

Maareynta Guud

Maareynta guud ee kansarka naasaha naasuhu waxay badanaa u tahay mid la yaab leh kuwa ku dhacay dib-u-soo-bax farabadan ka dib markii horeyba loo ogaado kansarka naasaha hore. Marka hore ee kansarka naasaha, daaweyntu badiyaa waa dagaal. Ujeedada daaweynta gardarrada leh qalliinka, kemotherabi, daaweynta la beegsado, iyo / ama shucaaca waa in laga hortago soo noqoshada haddii ay macquul tahay.

Marxalada 4 keli ah ee kansarka naaska ayaa hababku daaweyntu badiyaa ka duwan tahay, dad badan ayaana la yaab leh sababta ay ujeedadu u noqonayso mid dagaal badan (oo dareemeysa walwal sababtoo ah tan). Hadafka leh kansarka naasuhu waa caadi ahaan in la isticmaalo xaddiga ugu yar ee daaweynta loo baahan yahay si loo xakameeyo cudurka. Qeybta ugu badan, daaweynta aadka u daran ee marxaladda 4 Kansarka naasuhu ma hagaajinayo badbaadada, laakiin wuxuu kordhiyaa saameynta daawada. Tan macnaheedu waxa weeye in inta badan la isticmaalo kaliya hal nooc oo daaweyn ah waqti la isticmaalo (haddii ay hoos u dhigto koritaanka kansarka) halkii ay ka noqon lahayd hababka kala duwan ee la isu geeyey sida cudurka horey looqaaday.

Fursadaha Daaweynta

Daaweynta xariiqa koowaad ee kansarka naasuhu waa mid ku xiran inta badan xaalad qaadashada , iyo haddii ay tahay soo noqosho, labadaba xaaladaada estrogen iyo progesterone labadaba iyo xaaladda HER2 / neu waa in la baaraa (tan sida kor ku xusan, tani waxay bedeli kartaa.)

Haddii kaansarkaagu yahay labadaba astaamaha hormoonka estrogen iyo HER2 jawaabta, daaweynta bilowga ah waxaa ka mid noqon kara daaweynta hoormoonka , HER2 daaweynta loogu talagalay, ama labadaba. Go'aankani wuxuu ku xiran yahay daawooyinka lagaa daaweeyey ka hor inta aadan soo noqonin soo noqoshadaada (haddii kansarkaagu yahay dib-u-dhac fara badan halkii laga lahaa buro oo ah heerka 4 marka la ogaado cudurka.) Chemotherapy waxaa kaloo loo isticmaali karaa afar illaa lix bilood .

Haddii aadan horay loola dhaqmin daawada HER2, daaweynta waxaa badanaa la bilaabaa Herceptin (trastuzumab) ama Perjeta (pertuzumab). Kuwa horay loogu daaweeyay Herceptin, HER2 kale ayaa loo isticmaali karaa daroogada, sida Perjeta (pertuzumab). Xitaa dadka ku soo koray laba ka HER2 daawooyinka la beegsaday, daawaynta trastuzumab emtansine (TDM1) ayaa wanaajiyay guud ahaan badbaadada guud ee ka badan doorashooyinka kansarka ah ee hababka kale ee la heli karo (oo ay ka mid yihiin daawooyinka kemotherabi dhowr) hal daraasad.

Haddii kansarku uu ku sii socdo Herceptin ama 12 bilood gudahood joojinta daroogada, T-DM1 (trastuzumab emtansine) ayaa ah doorka la door bidaa labaad.

Khadadka sadarka sadexaad way kala duwanaan doonaan iyadoo ku xiran daaweynta hore. Kuwa aan weli la daaweynin T-DM1, kani waa ikhtiyaar. Perjeta ayaa sidoo kale loo isticmaali karaa dadka aan wali helin iyaga oo la socda Herceptin. Kuwa la daaweeyey Perjeta iyo T-DM1 oo wali sii wanaajin, doorashooyinka waxaa ka mid ah isku-dhafka Xeloda (capecitabine) iyo Tykerb (lapatinib), daaweynta hormoonka ee loogu talagalay dadka qaba hindhistaha 'positive estrogen receptor tumors', iyo hababka kale ee kemotherabi ee isku dhafan HER2 daroogooyinka lagu barto.

Daweynta Daawada Gaarka ah (Metastasis-Specific Treatment)

Daaweynta guud ee loo yaqaan 'metastases' (faafidda) kansarka naasaha ee goob kasta ayaa sida caadiga ah loola dhaqmaa daawooyinka hoormoonada, HER2 daaweynta isdabajoogga ah, ama daaweynta kiimikada. Tani waxay ku wareerin kartaa dadka qaarkood. Maxay tahay sababta unugyada kansarka ee sanbabada, tusaale ahaan, loola dhaqmaa daaweynta hoormoonka?

Waxaa muhiim ah in la ogaado marka kansarka naasaha uu ku faafo xubnaha kale, sida lafaha, maskaxda, beerka, iyo sanbabyada, waa unugyada kansarka naasaha ee ku fida xubnahaas.

Daweynada "metastasis-gaarka ah" ayaa sidoo kale loo isticmaali karaa. Kuwani waa daaweynyo si gaar ah wax uga qabta aagga mitirta, sida lafaha lafaha. Xanuunka beerka iyo maskaxda ayaa ku badan dumarka qaba HER2 / neu kansarka naasaha marka loo eego kuwa HER2 negative.

Qalabka lafaha

Lafo-ku-dul-qaadashada kansarka naasuhu waa wax aad u badan, oo lagu helo qiyaastii boqolkiiba 70 dadka qaba cudur-keena. Marka laga soo tago fursadaha daaweynta nidaamka daaweynta naasaha laftiisa, daaweynta metastasis gaar ah ee loogu talagalay daaweynta lafaha waxay hoos u dhigi kartaa xanuunka iyo sidoo kale wanaajinta badbaadada, iyo lafaha lafuhu waxay leeyihiin saadaalo fiican marka loo eego goobaha kale ee cudurada faafa. Xasuusta ayaa ah in dhibaatooyinka lafaha lafaha, sida jabka, ay noqdaan kuwo muhiim u ah inta badan daaweynta kansarka naasuhu waxay keeni kartaa laf jaban.

Fursadaha waxaa ka mid ah:

Iskuday beerka

Isku-duubnaanta beerka ee ka yimaadda kansarka naasku waa meesha labaad ee ugu badan ee metastaasta waxayna ku dhacdaa inta badan dadka qaba HER2 burooyin cajiib ah. Daweynta shucaaca waxaa inta badan loo isticmaalaa marka lagu daro daaweynta kale ee kansarka. Daawooyinka kale sida safmarinta ayaa la isticmaali karaa.

Haddii ay jiraan dhowr goobood oo metastasis ah (oligometastases) qaliinka saarista ama shucaaca jirka ee stereotactic wuxuu hagaajin karaa badbaadada. Daawada qanjirada beerka badanaa waxay keentaa ascites (barar caloosha) iyo paracentesis (ka qaadidda dheecaanka caloosha ilaa cirbadda dhuuban ee dheer) waxaa badanaa loo baahan yahay si loo yareeyo raaxo la'aanta. Cuncunku sidoo kale aad ayuu u badan yahay marka la eegayo beerka iyo daaweynta cuncunku waxay hagaajin kartaa tayada nolosha.

Maqaasiin Maskaxda

In kastoo ay la socdaan kaankarada kansarka naasaha inta badan loola dhaqmo sida qeyb ka mid ah daaweynta kansarka naasaha ee caadiga ah, maskaxda maskaxda ayaa noqon karta caqabad gaar ah. Cudurka dhiigga-maskaxdu waa mid si taxadar leh u shaqeeya oo ka hortagaya daawooyinka badan, oo ay ka mid yihiin daawooyinka kiimiko badan, oo ka yimaada maskaxda. Mahadsanid, daawooyinka qaar ayaa awood u leh in ay ka gudbaan cirifka

Dib u eegista qoraallada 2017-ka ayaa lagu ogaaday in Herceptin (trastuzumab) ay si cad u hagaajinayso noolaanshaha dadka qaba HER2 kansarka naasaha oo leh maskaxda. Trastuzumab emtansine (T-DM1) iyo Perjeta (pertuzumab) ayaa sidoo kale rajo leh. Tijaabo ahaan, Tykerb (lapatinib) ayaa u muuqda in ay saameyn yar ku yeeshaan maskaxda maskaxda (sida cilmibaarista 2017) oo leh qandho sarreysa. Marka lapatinib laysku geeyo kemotherabi, si kastaba ha ahaatee, qiimaha jawaabta ayaa ka fiican.

Mashiinka Lung-ka

Qanjirka naasuhu wuxuu ka yimaadaa kansarka naasaha inta badan waxaa lagu daaweeyaa tallaabooyin guud oo lagu daaweynayo kansarka naasaha, sida daaweynta hormoonnada, HER2 daawooyinka la bartilmaameedsaday, iyo daweynta kemotherabi, halkii ay ka ahaan lahayd daaweyn kasta oo gaar ah. Marka kaliya oo la socdo qiyaaso yar yar, daaweynta kuwan qalliinka ama SBRT ayaa laga yaabaa in la tixgeliyo, laakiin daraasaduhu weli wali waxay muujinayaan sicirka sii korodhka ah ee ka yimaada dhaqankan.

Metastases kale oo cidhiidhi ah

Kansarka naasuhu wuxuu ku faafi karaa gobollo kale oo fog oo jidhka ah, oo ay ku jiraan maqaarka, murqaha, unugyada dufanka, dhuuxa lafaha, iyo meelaha kale. Waqtiga intiisa badan waxaa la daaweeyaa daaweyn guud oo loogu talagalay daaweynta guud ee HER2 kansarka maqnaashaha, laakiin marka qulqulatooyinka cilladeysan ay dhacaan, fursadaha sida qalitaanka ama daaweynta shucaaca ayaa laga yaabaa in la tixgeliyo.

La qabsashada

La qabsashada kaankarada naasaha ee culus waa caqabad aan loo baahnayn nooca ama sheyga molecular. Haddii aad horey u qaadatay daaweynta cudurka horay iyo kansarkaaga oo soo noqnoqonaya, habka guud ee kansarka daaweynta ayaa laga yaabaa in uu marka hore u soo jiido, maaddaama ujeedadu ay tahay in la isticmaalo daaweyn yar sida ugu macquulsan si loo xakameeyo cudurka, laga yaabo inay yeeshaan kansarka naasaha hore.

Hadalka ah "waxay qaadataa tuulo" marna ma ahan mid ku haboon marka loo eego barta kansarka sare. Waxaa jira kooxo badan oo taageeraya iyo bulshooyinka kansarka naasaha oo la heli karo, laakiin dadka badankood ee qaba kansarka naasaha naasaha ayaa doorbidaya kooxo kuwaas oo ay ku jiraan kuwa ugu horreeya ee leh heerarka 4 kaankarada naasaha halkii ay ka mid yihiin dadka qaba kansarka naasaha hore.

Haddii ay tahay qofka aad jeceshahay oo ku noolyahay heerka 4 ee kansarka naasaha, qaado waqti aad ku barato waxyaabo aanad u sheegin qof qaba kansarka naasaha ee caadiga ah .

Ereyga

Daaweynta hormoonka HER2 ee kansarka naasaha waxaa laga yaabaa in lagu daaweeyo daawooyinka hoormoonka (hormoonada hormoonada hormoonka) iyo kuwa kiimiko ah, laakiin ikhtiyaarka ah in la isticmaalo daaweynta HER2 ee lagu beegsanayo ayaa sii dhigaya qaab kale.

HER2 burooyinka cajiibka ah waxay u badan tahay inay ku faafaan maskaxda iyo beerka marka loo eego HER2 burooyinka taban. Marka daaweynadani ay dhacaan, daaweynta guud iyo daaweynta gaarka ah ee metastasis ayaa laga yaabaa in la tixgeliyo. Nasiib wanaag, oo ka duwan daawooyinka badan, Herceptin iyo malaha pertuzumab waxay u muuqdaan inay ka gudbaan xuddunta dhiiga maskaxda si ay si wax ku ool ah ula tacaalaan mitiradan.

> Ilo:

> Dieras, V., Miles, D., Verma, S. et al. Trastuzumab Emtansine Versus Capecitabine Plus Lapatinib bukaanada Iyadoo hore loo daaweeyey HER2-Horumar Sarreysa Kansarka Naasaha (EMILIA): Falanqayn Sharaxaad leh Natiijada Ugu Danbeyn Natiijada Guud ee Ka Soo Noqoshada Ka-soocitaanka, Furan, Wajiga 3aad. Lancet Oncology . 2017. 18 (6): 732-742.

> Krop, I., Kim, S., Martin, A. et al. Trastuzumab Emtansine Versus Daaweynta Doorashada Dhakhtarka ee Bukaanka Iyadoo Hore u Habboon HER2-Kobcin Kacsan ee Kansarka Naasaha (TH3RESA): Natiijooyinka Ugu Muhiimsan ee Dhibaatada Laga Helo Wareegga Wareegga Wareegga 3-Marxaladood ee Furan. Lancet Oncology . 2017. 18 (6): 743-754.

> Laakmann, E., Muller, V., Schmidt, M. et al. Fursadaha Daaweynta Nidaamka ee HER2-Kansarka Naasaha ah ee Bukaan-jiifka leh ee Isku-dhafan ee Maskaxda Beyond Trastuzumab: Dib-u-eegista suugaanta. Daryeelka naaska . 2017. 12 (3): 168-171.